Testosterone Therapy Reduces Mortality Risk Among Diabetics Even When Accounting for Improvements in Cardiovascular Risk Factors

For men, Testosterone Replacement Therapy confers some fantastic benefits.

While there was a time not so long ago where Bio-Identical Testosterone was thought to have potentially adverse severe risks, recent research continues to provide increasing evidence that Testosterone Treatments are quite safe and provide excellent benefits for men nationwide struggling with Low-T.

While Testosterone was first used in adults for those struggling with low sex drive, erectile dysfunction, and fatigue, the range of patients that are believed to potentially benefit from Testosterone Restoration continues to broaden.

A recent study published by BJU International provides evidence that Testosterone Replacement Therapy is highly beneficial for patients dealing with the effects of Type-2 Diabetes.

Testosterone is increasingly prescribed to men struggling with Type-2 Diabetes because the condition can lead to severe disruption of Testosterone Production.

One of the objectives of this study was to differentiate whether the health benefits of Low-T Treatment are associated with a healthier cardiovascular system or some other factor or confluence of factors.

Does Testosterone Benefit Patients with Type-2 Diabetes?

It's been hypothesized that Bio-Identical Testosterone can mitigate mortality risk among males with Type-2 Diabetes.

This study provides evidence pointing toward that hypothesis, but it also appears to rule out improved Cardiovascular Health as a contributing factor toward that diminished mortality risk.

This study was conducted by Geoffery Hackett and a team of fellow researchers. The study was performed on behalf of the University Hospitals Birmingham National Health Service Foundation Trust. This study collected data from 857 males diagnosed with Type-2 Diabetes.

These patients were all drawn from participants screened for the BLAST Randomized Control Trial.

For this study, normal Testosterone baseline was considered a Free Testosterone of 0.25 nmol/L and Total Testosterone measuring more than 12 nmol/L.

Participants Organized By Testosterone Levels and Form of Treatment

These 857 subjects were split into different groups depending upon particular variables. Group One was comprised of men diagnosed with Type-2 Diabetes that measured normal Testosterone Levels. Members of Group 2 tested positive for Testosterone Deficiency based on the stated parameters.

These groups were further subdivided depending on whether they received Bio-Identical Testosterone for Hypogonadism (Group 2A received no treatment, and Group 2B received Testosterone Therapy).

Those that were diagnosed with Testosterone were further delineated into those that continued to take Testosterone and those that discontinued treatment (Group 2B1 stopped therapy, and Group 2B2 continued to receive Testosterone Treatments.)

Testosterone Therapy Diminishes Mortality Risk Among Men with Type-2 Diabetes

After these groups were separated, their information was analyzed concerning mortality risk using advanced Cox Regression Analyses.

The analysis showed that men with healthy Testosterone Levels and those using Bio-Identical Testosterone to bolster Free and Total Testosterone had lower Mortality risk than those that were not prescribed Therapeutic Testosterone. Participants were followed over 3.8 years.

This increase in mortality risk remained significant even when accounting for cholesterol, blood pressure, HbA1c Levels, and BMI.

Men that weighed less than 206 pounds and were more than 64.6 years old experienced the most significant benefits of reduced mortality risk.

Even Short-Term Low-T Treatment Provides Long-Term Benefits

The benefits associated with diminished risk of death by any cause was lower even among those that quit taking Testosterone Treatments. Those that never took Testosterone had a mortality rate of 16.9% over 3.8 years, while those that stopped using Testosterone only had a mortality rate of 6.2%.

No deaths were reported among those that continued to take Testosterone throughout the analysis.

Among patients that opted for Testosterone, the average length of treatment was a little over a year.

Men were initially treated with Testosterone Undecanoate Injections, though some guys opted for a Testosterone Gel later during Treatment.

To clean up the results, researchers took the time to account for any potential benefits that could be attributed to the use of PDE5 Inhibitors.

In the end, the investigators conclude that Bio-Identical Testosterone Therapy provides definite benefits to patients with comorbid Type-2 Diabetes and Testosterone Deficiency.

It also provides evidence that this reduction in mortality risk is not just the result of diminished Cardiovascular Disease Risk Factors.

Furthermore, if you do decide to opt into a Testosterone Replacement Therapy Program as a Type-2 Diabetic, the benefits will continue to remain apparent years after treatment has been discontinued.

While the gains were most notable among older patients, there's little reason not to adopt a quality Testosterone Regimen as soon as Low-T is diagnosed.

Interested In Bio-Identical Testosterone? We Can Help!

While Testosterone Replacement clearly provides benefits to eligible patients struggling with Type-2 Diabetes, this only represents a fraction of the patients that could ultimately experience an improved quality of life as a result of Therapeutic Testosterone.

Our Board Certified Wellness Clinic has improved the lives of hundreds of guys nationwide, and our Licensed HRT Specialists are extensively trained in advanced Hormone Therapy protocols.

If you're interested in Human Growth Hormone, Testosterone, or any other form of clinically evaluated Hormone Optimization, our qualified Hormone Doctors are just a phone call away!

References

Testosterone levels, testosterone therapy and all-cause mortality in men with type 2 diabetes

Reduced mortality with testosterone therapy unrelated to CVD risk factors in men with type 2 diabetes

Word Count: 864